Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Nov;66(5):884–891. doi: 10.1172/JCI109955

Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist.

C Dahinden, J Fehr
PMCID: PMC371522  PMID: 7430350

Abstract

The two pyrazolon derivatives, phenylbutazone and sulfinpyrazone, selectively inhibit chemotactic peptide-induced effects on neutrophils. As they antagonize the induction of acute neutropenia in vivo and of cellular hyperadhesiveness, lysosomal enzyme release, hexose monophosphate shunt activity, and superoxide production in vitro, these effects occur with a specificity not shared with other prostaglandin biosynthesis inhibition by these drugs resembles the competitive type of antagonism and occurs at concentrations attainable in vivo under clinical conditions. The locomotory machinery, the direction-finding mechanisms, and the basic metabolic machinery of the cell are unaffected. These drugs interfere with specific binding of the formylpeptide to its receptor on neutrophils.

Full text

PDF
884

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austen K. F. Homeostasis of effector systems which can also be recruited for immunologic reactions. J Immunol. 1978 Sep;121(3):793–805. [PubMed] [Google Scholar]
  2. Baenziger N. L., Becherer P. R., Majerus P. W. Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts. Cell. 1979 Apr;16(4):967–974. doi: 10.1016/0092-8674(79)90111-9. [DOI] [PubMed] [Google Scholar]
  3. Becker E. L. A multifunctional receptor on the neutrophil for synthetic chemotactic oligopeptides. J Reticuloendothel Soc. 1979 Dec;26(Suppl):701–709. [PubMed] [Google Scholar]
  4. Bokoch G. M., Reed P. W. Inhibition of the neutrophil oxidative response to a chemotactic peptide by inhibitors of arachidonic acid oxygenation. Biochem Biophys Res Commun. 1979 Sep 27;90(2):481–487. doi: 10.1016/0006-291x(79)91260-9. [DOI] [PubMed] [Google Scholar]
  5. Braunwald E. Treatment of the patient after myocardial infarction. The last decade and the next. N Engl J Med. 1980 Jan 31;302(5):290–293. doi: 10.1056/NEJM198001313020510. [DOI] [PubMed] [Google Scholar]
  6. Cohen H. J., Chovaniec M. E. Superoxide generation by digitonin-stimulated guinea pig granulocytes. A basis for a continuous assay for monitoring superoxide production and for the study of the activation of the generating system. J Clin Invest. 1978 Apr;61(4):1081–1087. doi: 10.1172/JCI109007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dieterle W., Faigle J. W., Mory H., Richter W. J., Theobald W. Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):135–145. doi: 10.1007/BF00614010. [DOI] [PubMed] [Google Scholar]
  8. Fehr J., Dahinden C. Modulating influence of chemotactic factor-induced cell adhesiveness on granulocyte function. J Clin Invest. 1979 Jul;64(1):8–16. doi: 10.1172/JCI109466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fehr J., Jacob H. S. In vitro granulocyte adherence and in vivo margination: two associated complement-dependent functions. Studies based on the acute neutropenia of filtration leukophoresis. J Exp Med. 1977 Sep 1;146(3):641–652. doi: 10.1084/jem.146.3.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. GOTTLIEBLAU K. S., WASSERMAN L. R., HERBERT V. RAPID CHARCOAL ASSAY FOR INTRINSIC FACTOR (IF), GASTRIC JUICE UNSATURATED B12 BINDING CAPACITY, ANTIBODY TO IF, AND SERUM UNSATURATED B12 BINDING CAPACITY. Blood. 1965 Jun;25:875–884. [PubMed] [Google Scholar]
  11. Goldstein I. M. Editorial: Endogenous regulation of complement (C5)-derived chemotactic activity: fine-tuning of inflammation. J Lab Clin Med. 1979 Jan;93(1):13–16. [PubMed] [Google Scholar]
  12. Goldstein I. M., Malmsten C. L., Kindahl H., Kaplan H. B., Rådmark O., Samuelsson B., Weissmann G. Thromboxane generation by human peripheral blood polymorphonuclear leukocytes. J Exp Med. 1978 Sep 1;148(3):787–792. doi: 10.1084/jem.148.3.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Holmes B., Good R. A. Laboratory models of chronic granulomatous disease. J Reticuloendothel Soc. 1972 Aug;12(2):216–237. [PubMed] [Google Scholar]
  14. Kane S. P., Peters T. J. Analytical subcellular fractionation of human granulocytes with reference to the localization of vitamin B12-binding proteins. Clin Sci Mol Med. 1975 Aug;49(2):171–182. doi: 10.1042/cs0490171. [DOI] [PubMed] [Google Scholar]
  15. Kaplan L., Weiss J., Elsbach P. Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1978 Jun;75(6):2955–2958. doi: 10.1073/pnas.75.6.2955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lecaillon J. B., Souppart C. Quantitative assay of sulphinpyrazone in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1976 Jun 23;121(2):227–234. doi: 10.1016/s0021-9673(00)85018-9. [DOI] [PubMed] [Google Scholar]
  17. Lehmeyer J. E., Snyderman R., Johnston R. B., Jr Stimulation of neutrophil oxidative metabolism by chemotactic peptides: influence of calcium ion concentration and cytochalasin B and comparison with stimulation by phorbol myristate acetate. Blood. 1979 Jul;54(1):35–45. [PubMed] [Google Scholar]
  18. Lehrer R. I., Cline M. J. Interaction of Candida albicans with human leukocytes and serum. J Bacteriol. 1969 Jun;98(3):996–1004. doi: 10.1128/jb.98.3.996-1004.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Libby P., Maroko P. R., Bloor C. M., Sobel B. E., Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest. 1973 Mar;52(3):599–607. doi: 10.1172/JCI107221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Maroko P. R., Carpenter C. B., Chiariello M., Fishbein M. C., Radvany P., Knostman J. D., Hale S. L. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest. 1978 Mar;61(3):661–670. doi: 10.1172/JCI108978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nelson R. D., Ackerman S. K., Fiegel V. D., Bauman M. P., Douglas S. D. Cytotaxin receptors of neutrophils: evidence that F-methionyl peptides and pepstatin share a common receptor. Infect Immun. 1979 Dec;26(3):996–999. doi: 10.1128/iai.26.3.996-999.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Niedel J. E., Kahane I., Cuatrecasas P. Receptor-mediated internalization of fluorescent chemotactic peptide by human neutrophils. Science. 1979 Sep 28;205(4413):1412–1414. doi: 10.1126/science.472759. [DOI] [PubMed] [Google Scholar]
  23. Niedel J., Wilkinson S., Cuatrecasas P. Receptor-mediated uptake and degradation of 125I-chemotactic peptide by human neutrophils. J Biol Chem. 1979 Nov 10;254(21):10700–10706. [PubMed] [Google Scholar]
  24. O'Flaherty J. T., Showell H. J., Becker E. L., Ward P. A. Role of arachidonic acid derivatives in neutrophil aggregation: a hypothesis. Prostaglandins. 1979 Jun;17(6):915–927. doi: 10.1016/0090-6980(79)90062-5. [DOI] [PubMed] [Google Scholar]
  25. O'Flaherty J. T., Showell H. J., Ward P. A. Neutropenia induced by systemic infusion of chemotactic factors. J Immunol. 1977 May;118(5):1586–1589. [PubMed] [Google Scholar]
  26. Quie P. G., Cates K. L. Clinical conditions associated with defective polymorphonuclear leukocyte chemotaxis. Am J Pathol. 1977 Sep;88(3):711–726. [PMC free article] [PubMed] [Google Scholar]
  27. Sacks T., Moldow C. F., Craddock P. R., Bowers T. K., Jacob H. S. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest. 1978 May;61(5):1161–1167. doi: 10.1172/JCI109031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Schiffmann E., Corcoran B. A., Wahl S. M. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A. 1975 Mar;72(3):1059–1062. doi: 10.1073/pnas.72.3.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Smolen J. E., Weissmann G. Effects of indomethacin, 5,8,11,14-eicosatetraynoic acid, and p-bromophenacyl bromide on lysosomal enzyme release and superoxide anion generation by human polymorphonuclear leukocytes. Biochem Pharmacol. 1980 Feb 15;29(4):533–538. doi: 10.1016/0006-2952(80)90373-1. [DOI] [PubMed] [Google Scholar]
  30. Stossel T. P. Phagocytosis (third of three parts). N Engl J Med. 1974 Apr 11;290(15):833–839. doi: 10.1056/NEJM197404112901506. [DOI] [PubMed] [Google Scholar]
  31. Strauss R. R., Paul B. B., Sbarra A. J. Effect of phenylbutazone on phagocytosis and intracellular killing by guinea pig polymorphonuclear leukocytes. J Bacteriol. 1968 Dec;96(6):1982–1990. doi: 10.1128/jb.96.6.1982-1990.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Williams L. T., Snyderman R., Pike M. C., Lefkowitz R. J. Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1204–1208. doi: 10.1073/pnas.74.3.1204. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES